Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Dow
Farmers Insurance
Cipla
Julphar
Healthtrust
US Department of Justice
Covington
Cerilliant
Chubb

Generated: October 20, 2017

DrugPatentWatch Database Preview

Antares Pharma Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ANTARES PHARMA INC, and when can generic versions of ANTARES PHARMA INC drugs launch?

ANTARES PHARMA INC has two approved drugs.

There are thirteen US patents protecting ANTARES PHARMA INC drugs.

There are thirty-four patent family members on ANTARES PHARMA INC drugs in twelve countries.

Summary for Applicant: Antares Pharma Inc

International Patents:34
US Patents:13
Tradenames:3
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-001Oct 11, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-002Oct 11, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-004Oct 11, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-004Oct 11, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-004Oct 11, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-002Oct 11, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-007Mar 24, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-003Oct 11, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-005Nov 7, 2014DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-005Nov 7, 2014DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Antares Pharma Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,428,528 Needle assisted jet injector► Subscribe
9,750,881Hazardous agent injection system► Subscribe
6,565,553 Needle assisted jet injector► Subscribe
9,180,259Prefilled syringe jet injector► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Antares Pharma Inc Drugs

Country Document Number Estimated Expiration
Japan4299466► Subscribe
China101132820► Subscribe
Japan2015042270► Subscribe
Germany69921704► Subscribe
Japan5732039► Subscribe
European Patent Office1850892► Subscribe
Austria240756► Subscribe
China1212867► Subscribe
China102612381► Subscribe
European Patent Office1104317► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Queensland Health
Argus Health
UBS
Dow
Daiichi Sankyo
Teva
Chubb
Healthtrust
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot